TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12969102

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 micro g) plus plain bupivacaine (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (50 micro g) plus plain bupivacaine (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain bupivacaine (10 mg) with saline (control)
Number of subjects: 60
Study: 10636148

Group type: EXPERIMENTAL
Intervention: 1.6 mIU IFNbeta‐1b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 mIU IFNbeta‐1b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9387742

Group type: EXPERIMENTAL
Intervention: Radix Salviae Miltiorrhizae (RSM) treatment group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 1390605

Group type: EXPERIMENTAL
Intervention: Chromium-rich yeast (160 micrograms Cr/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3885424

Group type: EXPERIMENTAL
Intervention: isoxicam 200 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: naproxen 250 mg 3 times daily
Number of subjects: 30
Study: 31456982

Group type: EXPERIMENTAL
Intervention: Husband participation with 2 training sessions and telephone counseling
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine pregnancy care (Control)
Number of subjects: 66
Study: 29972757

Group type: EXPERIMENTAL
Intervention: Inotersen (300 mg weekly subcutaneous injections)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 26497268

Group type: EXPERIMENTAL
Intervention: Win feedback preceded by wins at Outcomet-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Win feedback preceded by losses at Outcomet-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loss feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outcomet-2
Number of subjects: 0
Study: 24488080

Group type: EXPERIMENTAL
Intervention: Vitamin D (700 IU/day) and Calcium (500 mg/day)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 22747608

Group type: EXPERIMENTAL
Intervention: 9-week dance program with 2, 90-minute dance classes per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with incentives for data collection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with incentives and a delayed dance workshop
Number of subjects: 40
Study: 21223651

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine mask combined with skin care (treatment group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Common commercial beauty mask (control group)
Number of subjects: 41
Study: 17433791

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Equal contact exercise-placebo intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study: 16261200

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b nasal spray (9 x 10(5) IU, twice per day for 5 days)
Number of subjects: 14391

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b nasal spray
Number of subjects: 14391
Study: 12137101

Group type: EXPERIMENTAL
Intervention: 5 short breaks spaced hourly during cruise
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1 break in the middle of cruise (Control)
Number of subjects: 28
Study: 9708636

Group type: EXPERIMENTAL
Intervention: Folinic acid (FA; 500 mg/mq in 2‐hour intravenous infusion) and 5‐fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA) without hydroxyurea (HU) (arm A)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Folinic acid (FA; 500 mg/mq in 2‐hour intravenous infusion) and 5‐fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA) with hydroxyurea (35 mg/kg per day) (arm B)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Comparison of both arms (A and B)
Number of subjects: 182
Study: 7619975

Group type: EXPERIMENTAL
Intervention: 35% CO2-65% O2 inhalation during early-follicular phase
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 35% CO2-65% O2 inhalation during midluteal phase
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no CO2 inhalation)
Number of subjects: 17
Study: 2244643

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 485645

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate, 50 mg/day for 100 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clomiphene citrate, 50 mg/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clomiphene therapy
Number of subjects: 105
Study: 31718657

Group type: EXPERIMENTAL
Intervention: Dermal carotenoids measured by resonance Raman spectroscopy (RRS)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Self-reported fruit and vegetable intake (FVI) measures
Number of subjects: 157
Study: 27310238

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 2140

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 2140
Study: 26796455

Group type: EXPERIMENTAL
Intervention: 180-degree laser photolysis (LP) treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 360-degree laser photolysis (LP) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 28
Study: 23242584

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Combination score of positive pathway markers (p‐Akt, p‐mTOR, p‐ER)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Nuclear p‐Akt‐s473 and p‐ER at ‐s167 and/or ‐s305
Number of subjects: 912

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 912
Study: 21762157

Group type: EXPERIMENTAL
Intervention: 0.1% w/w o-cymen-5-ol/ 0.6% w/w zinc chloride/ sodium fluoride dentifrice
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 75
Study: 19689079

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 2556

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2556
Study: 17116767

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 297
Study: 14574515

Group type: EXPERIMENTAL
Intervention: Intravenous cholecystokinin (CCK-8) infusion at 10 ng/kg over 3 min
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Opioid group (no intervention specified)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SOS group (no intervention specified)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SOS group (after treatment with antispasmodics or endoscopic sphincterotomy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SOS group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Opioid group
Number of subjects: 28
Study: 11737926

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (1 unit of packed RBC over 1 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% albumin solution (500 ml over 1 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% albumin solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 15
Study: 9613407

Group type: EXPERIMENTAL
Intervention: Written warnings
Number of subjects: 269

Group type: COMPARATOR
Intervention: Verbal warnings
Number of subjects: 269
Study: 8221707

Group type: EXPERIMENTAL
Intervention: Single oral dose of 30 mg of nicardipine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chronic treatment with nicardipine (60 mg/day for 1 month)
Number of subjects: 11
Study: 3120764

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 1 min before induction of anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard technique of general anaesthesia without alfentanil)
Number of subjects: 0
Study: 31358721

Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam 40 mg 1 hour prior to surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo 1 hour prior to surgery
Number of subjects: 40
Study: 30152808

Group type: COMPARATOR
Intervention: RMsham (sham roller massage)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RMmod (moderate roller massage)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RMhigh (high roller massage)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All RM conditions (RMsham, RMmod, RMhigh)
Number of subjects: 16
Study: 26319616

Group type: EXPERIMENTAL
Intervention: Better Beginnings, Better Futures (BBBF) initiative
Number of subjects: 626
Study: 25286986

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ATII) infusion at a starting dose of 20 ng/kg/min, titrated to maintain MAP of 65 mmHg for 6 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ATII) infusion
Number of subjects: 20
Study: 22405707

Group type: EXPERIMENTAL
Intervention: Intervention (persuasive material about canine health from walking and a calendar to mark walks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard control condition
Number of subjects: 58
Study: 21165231

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification
Number of subjects: 85

Group type: COMPARATOR
Intervention: Longitudinal phacoemulsification
Number of subjects: 85
Study: 17671394

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 2775

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2775
Study: 15682368

Group type: EXPERIMENTAL
Intervention: Gated SPECT
Number of subjects: 20

Group type: COMPARATOR
Intervention: RNA
Number of subjects: 20
Study: 11919305

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy
Number of subjects: 309
Study: 9949315

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 879
Study: 7769301

Group type: EXPERIMENTAL
Intervention: Menfegol foaming tablets used once every other day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Menfegol foaming tablets used 1 time a day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Menfegol foaming tablets used 2 times a day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Menfegol foaming tablets used 4 times a day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Menfegol foaming tablets used 8 times a day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo tablets used < 8 times daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo tablets used 8 times daily
Number of subjects: 125
Study: 2162749

Group type: EXPERIMENTAL
Intervention: (R,S)-propafenone hydrochloride 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (S)-propafenone hydrochloride 150 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: (R)-propafenone hydrochloride 150 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (R)-propafenone 3 x 10(−6) mol/L
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (S)-propafenone 3 x 10(−6) mol/L
Number of subjects: 8
Study: 383553

Group type: EXPERIMENTAL
Intervention: Rifaprim (rifampicin 600 mg plus trimethoprim 160 mg, single daily dose at 10 p.m.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cotrimoxazole (two tablets b.i.d.)
Number of subjects: 42
Study: 31551097

Group type: EXPERIMENTAL
Intervention: SCOTT (social-cognitive training)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-social computer training (active control)
Number of subjects: 48
Study: 31794034

Group type: EXPERIMENTAL
Intervention: Simulation-based deliberate practice
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 132
Study: 28733854

Group type: EXPERIMENTAL
Intervention: Support to stay in school (tuition, uniform, nurse visits)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Nurse visits
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Attending boarding school
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: School fees and uniforms
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 412
Study: 26108785

Group type: EXPERIMENTAL
Intervention: R118
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23864006

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 549

Group type: COMPARATOR
Intervention: Right ventricle‐pulmonary artery shunt
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Intervention for recoarctation (catheter based or surgical)
Number of subjects: 549
Study: 21551025

Group type: EXPERIMENTAL
Intervention: Limited health literacy defined as a REALM score ≤60
Number of subjects: 288

Group type: COMPARATOR
Intervention: Demographic and clinical characteristics
Number of subjects: 288

Group type: COMPARATOR
Intervention: Age, gender, serologic values, dialysis adequacy, overall symptom burden, quality of life, depression
Number of subjects: 288
Study: 19196673

Group type: COMPARATOR
Intervention: Capecitabine, oxaliplatin, and bevacizumab (CB regimen)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, bevacizumab plus weekly cetuximab (CBC regimen)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Cetuximab in patients with mutated KRAS gene
Number of subjects: 755
Study: 17223390

Group type: EXPERIMENTAL
Intervention: Pain recall assessed by treating physician
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pain recall assessed by research assistant
Number of subjects: 70
Study: 15212355

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 75
Study: 11450927

Group type: EXPERIMENTAL
Intervention: Community pharmacy consultation for head lice treatment
Number of subjects: 0
Study: 9503220

Group type: EXPERIMENTAL
Intervention: Somatostatin administration over a 10-day period
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 50
Study: 7800129

Group type: EXPERIMENTAL
Intervention: Multidrug chemotherapy (6‐thioguanine, dibromodulcitol, procarbazine, 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea, 5‐fluorouracil, and hydroxyurea)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Multidrug chemotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Greater surgical debulking and smaller postoperative tumor volumes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Greater myelotoxicity
Number of subjects: 51
Study: 3054094

Group type: EXPERIMENTAL
Intervention: Diclofenac, 150 mg/day
Number of subjects: 417

Group type: COMPARATOR
Intervention: Aspirin, 3.6 g/day
Number of subjects: 417

Group type: COMPARATOR
Intervention: Naproxen, 1000 mg/day
Number of subjects: 417
Study: 29974228

Group type: EXPERIMENTAL
Intervention: Curcumin with LipiSperse® delivery system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Raw curcumin product
Number of subjects: 18
Study: 27849639

Group type: EXPERIMENTAL
Intervention: WeCareAdvisor (web-based caregiver support tool)
Number of subjects: 38
Study: 25414173

Group type: EXPERIMENTAL
Intervention: Prostacyclin 1 ng/kg per minute
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prostacyclin 2 ng/kg per minute
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 23295274

Group type: EXPERIMENTAL
Intervention: EQUIP training for endoscopists
Number of subjects: 15

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 15
Study: 22104620

Group type: EXPERIMENTAL
Intervention: Increased levels of norepinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infarction of the anterior MCA cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large stroke volume and lesions affecting distinct regions of the MCA cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sympathetic nerve system (SNS) activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stroke severity and stroke volume
Number of subjects: 0
Study: 18512093

Group type: EXPERIMENTAL
Intervention: Hypothermia cap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no prehospital cooling)
Number of subjects: 20
Study: 17000786

Group type: EXPERIMENTAL
Intervention: Clonidine (1 microg kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12914551

Group type: EXPERIMENTAL
Intervention: 5 micro g/kg of APO
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 micro g/kg of APO
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 micro g/kg of APO
Number of subjects: 18
Study: 10740546

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Desflurane anaesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison of inhalation anaesthetics
Number of subjects: 84
Study: 8752016

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1281905

Group type: EXPERIMENTAL
Intervention: Alternating COPP/ABVD chemotherapy +/‐ radiotherapy
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Radiation alone
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Conventional salvage treatment
Number of subjects: 297

Group type: COMPARATOR
Intervention: High-dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT)
Number of subjects: 297
Study: 6726600

Group type: EXPERIMENTAL
Intervention: Fake-aggressive group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fake-nonaggressive group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard-instruction control group
Number of subjects: 58
Study: 31248067

Group type: EXPERIMENTAL
Intervention: Usual Western‐style diet enriched with 60 g/day of a mixture of nuts (nut group; n = 43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual Western‐style diet avoiding nuts (control group; n = 40)
Number of subjects: 83
Study: 29952993

Group type: EXPERIMENTAL
Intervention: Dry Needling + Exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham Dry Needling + Exercise
Number of subjects: 20
Study: 27116006

Group type: EXPERIMENTAL
Intervention: PRET device (automated transfer pump)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Manual transfer
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfers with PRET
Number of subjects: 599

Group type: COMPARATOR
Intervention: Frozen-thawed embryo transfers with manual transfer
Number of subjects: 599
Study: 25018121

Group type: EXPERIMENTAL
Intervention: Once-weekly dulaglutide (1.5 mg)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Once-daily liraglutide (1.8 mg)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Comparison of dulaglutide vs liraglutide
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Once-weekly dulaglutide
Number of subjects: 599

Group type: COMPARATOR
Intervention: Once-daily liraglutide
Number of subjects: 599

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 599
Study: 21915624

Group type: EXPERIMENTAL
Intervention: GMA adjusted to patients' body weight (BW), 60 mL/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine GMA (fixed at 30 mL/min × 60 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GMA adjusted to patients' BW
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine GMA
Number of subjects: 60
Study: 20613676

Group type: EXPERIMENTAL
Intervention: Vitamin D intake (less than 100, 100 to 199, 200 to 399, 400 to 599, and 600 or greater IU/day)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Calcium intake (less than 500, 500 to 749, 750 to 999, 1,000 to 1,199, and 1,200 or greater mg/day)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D use
Number of subjects: 808
Study: 17283364

Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide (FC arm)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Fludarabine (F arm)
Number of subjects: 278
Study: 16054549

Group type: EXPERIMENTAL
Intervention: Oat bran flour
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oat bran crisp
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose load
Number of subjects: 12
Study: 12362376

Group type: EXPERIMENTAL
Intervention: Bone Morphing method for TKA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluoroscopic assessment of soft-tissue balancing
Number of subjects: 35
Study: 11603418

Group type: EXPERIMENTAL
Intervention: Spironolactone at a mean dose of 25 mg/day
Number of subjects: 0
Study: 8996753

Group type: EXPERIMENTAL
Intervention: Azathioprine withdrawal (tapered over 1 year)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Azathioprine (continued)
Number of subjects: 172
Study: 1592448

Group type: EXPERIMENTAL
Intervention: Sodium chloride (200 mmol/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium citrate (200 mmol/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium chloride and sodium citrate (200 mmol/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6370155

Group type: EXPERIMENTAL
Intervention: Preoperative carcinoembryonic antigen (CEA) levels
Number of subjects: 945
Study: 30288843

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 60 seconds
Number of subjects: 51

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) at 15 seconds
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 51